An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Ribociclib|DRUG: T-DM1|DRUG: Trastuzumab|DRUG: Fulvestrant
Sponsor: Dana-Farber Cancer Institute
Collaborators: Novartis